Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices 49389 

Site Studies for System-Level 

Implementation of Substance Use Prevention 

and Treatment Services (R01; R34). 

Date: November 7, 2017. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, DHHS, 6001 

Executive Blvd., Room 4238, MSC 9550, 

Bethesda, MD 20892–9550, 301–827–5819, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Limited 

Competition—Cohort Studies of HIV/AIDS 

and Substance Abuse (U01). 

Date: November 7, 2017. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Hiromi Ono, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Boulevard, 

Room 4238, MSC 9550, Bethesda, MD 20892, 

301–827–5820, hiromi.ono@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Advancing Exceptional Research on HIV/ 

AIDS and Substance Abuse (R01). 

Date: November 10, 2017. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Hiromi Ono, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Boulevard, 

Room 4238, MSC 9550, Bethesda, MD 20892, 

301–827–5820, hiromi.ono@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Wearable to Track Recovery and Relapse 

Factors for People w/Addiction (R43, R44). 

Date: November 21, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Julia Berzhanskaya, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4234, MSC 9550, Bethesda, 

MD 20892, 301–827–5840, 

julia.berzhanskaya@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Research Education Program for Clinical 

Researchers and Clinicians (R25). 

Date: December 4, 2017. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, DHHS, 6001 

Executive Blvd., Room 4238, MSC 9550, 

Bethesda, MD 20892–9550, 301–827–5819, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Nasal 

Delivery of CNS Therapeutics (R41, R42, R43, 

R44). 

Date: December 5, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Julia Berzhanskaya, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4234, MSC 9550, Bethesda, 

MD 20892, 301–827–5840, 

julia.berzhanskaya@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Conference Grant Review (R13). 

Date: December 6, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Shang-Yi Anne Tsai, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4228, MSC 9550, Bethesda, 

MD 20892, 301–827–5842, shangyi.tsai@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: October 19, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–23128 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Amy Petrik, 240–627–3721; 

amy.petrik@nih.gov. Licensing 

information and copies of the U.S. 

patent application listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD, 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Neutralizing Antibodies to Influenza 

HA and Their Use and Identification 

Description of Technology: The 

effectiveness of current influenza 

vaccines varies by strain and season, in 

part because influenza viruses 

continuously evolve to evade human 

immune responses. While the majority 

of seasonal influenza infections cause 

relatively mild symptoms, each year 

influenza virus infections result in over 

500,000 hospitalizations in the United 

States and Europe. Current standard of 

care for individuals hospitalized with 

uncomplicated influenza infection is 

administration of neuraminidase 

inhibitors. However, frequent use of 

such antiviral drugs increases the risk 

that the virus will develop drug 

resistance, especially in high-risk 

populations. Thus, alternative strategies 

are required to protect or treat 

vulnerable populations who have been 

hospitalized with severe influenza. 

Using a combination of recombinant 

proteins and sophisticated flow 

cytometry, scientists at NIAID isolated 

families of antibodies capable of 


sradovich on DSK3GMQ082PROD with NOTICES
49390 Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices 

neutralizing diverse group 1 and group 

2 influenza A viruses. Specifically, the 

families of antibodies identified 

precisely target parts of the 

hemagglutinin (HA) protein, present on 

the surface of the influenza virus, that 

are least variable from season to season 

(Joyce, M.G., et al. Cell (2016) 166 (3): 

609–623). Therefore, it is hypothesized 

that passive administration of members 

of these families of antibodies to 

individuals would represent an 

alternative to the current standard of 

care for severe influenza virus infection. 

Additionally, these families of 

antibodies could be useful for 

development of a product aimed at 

conferring passive immunity in 

vulnerable populations during the time 

of an outbreak or emergence of a 

pandemic strain of influenza. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

NIAID is continuing development of 

these neutralizing antibodies to 

influenza toward a clinical product for 

treatment and/or prevention of 

influenza virus infection. Consequently, 

for some fields of use, NIAID will 

evaluate a license applicant’s 

capabilities and experience in 

advancing similar technologies through 

the regulatory process. 

Potential Commercial Applications: 

• Prevention of influenza A virus 

infection 

• Therapeutic intervention to treat 

influenza infection 

Competitive Advantages: 

• Ability to potently neutralize both 

group 1 and group 2 influenza A strains 

Development Stage: 

• Proof of concept in animal models 

Inventors: Adrian McDermott (NIAID), 

Peter Kwong (NIAID), John Mascola 

(NIAID), M. Gordon Joyce (NIAID), 

Robert Bailer (NIAID), Sarah Andrews 

(NIAID), Paul Thomas (NIAID), Gwo-Yu 

Chuang (NIAID), Adam Wheatley 

(NIAID), Yi Zhang (NIAID), James 

Whittle (NIAID). 

Publications: Joyce, M.G., et al. Cell 

(2016) 166 (3): 609–623 

Intellectual Property: HHS Reference 

No. E–061–2016—US Patent 

Application No. 62/330,837 filed May 2, 

2016; Patent Cooperation Treaty 

Application No. PCT/US2017/030641 

filed May 2, 2017. 

Licensing Contact: Dr. Amy Petrik, 

240–627–3721; amy.petrik@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize influenza monoclonal 

antibody technologies. For collaboration 

opportunities, please contact Dr. Amy 

Petrik, 240–627–3721; amy.petrik@

nih.gov. 

Dated: October 19, 2017. 

Suzanne Frisbie, 

Deputy Director,Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–23177 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2017–0124] 

Collection of Information Under 

Review by Office of Management and 

Budget; OMB Control Number: 1625– 

0057 

AGENCY: Coast Guard, DHS. 

ACTION: Thirty-day notice requesting 

comments. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995 the 

U.S. Coast Guard is forwarding an 

Information Collection Request (ICR), 

abstracted below, to the Office of 

Management and Budget (OMB), Office 

of Information and Regulatory Affairs 

(OIRA), requesting approval for 

reinstatement, without change, of the 

following collection of information: 

1625–0057, Small Passenger Vessels— 

Title 46 Subchapters K and T. Our ICR 

describes the information we seek to 

collect from the public. Review and 

comments by OIRA ensure we only 

impose paperwork burdens 

commensurate with our performance of 

duties. 

DATES: Comments must reach the Coast 

Guard and OIRA on or before November 

24, 2017. 

ADDRESSES: You may submit comments 

identified by Coast Guard docket 

number [USCG–2017–0124] to the Coast 

Guard using the Federal eRulemaking 

Portal at http://www.regulations.gov. 

Alternatively, you may submit 

comments to OIRA using one of the 

following means: 

(1) Email: dhsdeskofficer@

omb.eop.gov. 

(2) Mail: OIRA, 725 17th Street NW., 

Washington, DC 20503, attention Desk 

Officer for the Coast Guard. 

A copy of the ICR is available through 

the docket on the Internet at http://

www.regulations.gov. Additionally, 

copies are available from: Commandant 

(CG–612), Attn: Paperwork Reduction 

Act Manager, U.S. Coast Guard, 2703 

Martin Luther King Jr. Ave. SE., Stop 

7710, Washington, DC 20593–7710. 

FOR FURTHER INFORMATION: Contact Mr. 

Anthony Smith, Office of Information 

Management, telephone 202–475–3532, 

or fax 202–372–8405, for questions on 

these documents. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

This Notice relies on the authority of 

the Paperwork Reduction Act of 1995; 

44 U.S.C. Chapter 35, as amended. An 

ICR is an application to OIRA seeking 

the approval, extension, or renewal of a 

Coast Guard collection of information 

(Collection). The ICR contains 

information describing the Collection’s 

purpose, the Collection’s likely burden 

on the affected public, an explanation of 

the necessity of the Collection, and 

other important information describing 

the Collection. There is one ICR for each 

Collection. 

The Coast Guard invites comments on 

whether this ICR should be granted 

based on the Collection being necessary 

for the proper performance of 

Departmental functions. In particular, 

the Coast Guard would appreciate 

comments addressing: (1) The practical 

utility of the Collection; (2) the accuracy 

of the estimated burden of the 

Collection; (3) ways to enhance the 

quality, utility, and clarity of 

information subject to the Collection; 

and (4) ways to minimize the burden of 

the Collection on respondents, 

including the use of automated 

collection techniques or other forms of 

information technology. These 

comments will help OIRA determine 

whether to approve the ICR referred to 

in this Notice. 

We encourage you to respond to this 

request by submitting comments and 

related materials. Comments to Coast 

Guard or OIRA must contain the OMB 

Control Number of the ICR. They must 

also contain the docket number of this 

request, [USCG–2017–0124], and must 

be received by November 24, 2017. 

Submitting Comments 

We encourage you to submit 

comments through the Federal 

eRulemaking Portal at http://

www.regulations.gov. If your material 

cannot be submitted using http://

www.regulations.gov, contact the person 

in the FOR FURTHER INFORMATION

CONTACT section of this document for 

alternate instructions. Documents 

mentioned in this notice, and all public 


sradovich on DSK3GMQ082PROD with NOTICES